Portola Pharmaceuticals, Inc.: Dr. John Curnutte, M.D., Ph.D., executive vice president and head of R&D, will retire on May 17, 2019, after more than eight years of service. Dr. Curnutte will remain in a consultancy role, providing guidance to Portola’s president and chief executive officer Scott Garland and engaging with key academic and scientific thoughtleaders in the field on the ongoing development of Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] and cerdulatinib. O...